[go: up one dir, main page]

MX2020002150A - Terapia de combinación para el tratamiento del cáncer. - Google Patents

Terapia de combinación para el tratamiento del cáncer.

Info

Publication number
MX2020002150A
MX2020002150A MX2020002150A MX2020002150A MX2020002150A MX 2020002150 A MX2020002150 A MX 2020002150A MX 2020002150 A MX2020002150 A MX 2020002150A MX 2020002150 A MX2020002150 A MX 2020002150A MX 2020002150 A MX2020002150 A MX 2020002150A
Authority
MX
Mexico
Prior art keywords
agent
pharmaceutically acceptable
acceptable salt
cancer
treatment
Prior art date
Application number
MX2020002150A
Other languages
English (en)
Other versions
MX384403B (es
Inventor
Yan Chen
Xizhong Huang
Sunkyu Kim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020002150(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020002150A publication Critical patent/MX2020002150A/es
Publication of MX384403B publication Critical patent/MX384403B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende (1) un primer agente el cual es un inhibidor de CDK o una sal farmacéuticamente aceptable del mismo y (2) un segundo agente, el cual es un agente anti-hormonal, o una sal farmacéuticamente aceptable del mismo. La presente invención se refiere a una combinación farmacéutica que comprende (1) un primer agente el cual es un inhibidor de CDK o una sal farmacéuticamente aceptable del mismo y (2) un segundo agente, el cual es un agente anti-hormonal, o una sal farmacéuticamente aceptable del mismo, y (3) un tercer agente el cual es un agente que regula la vía PI3K/Akt/mTOR o una sal farmacéuticamente aceptable del mismo.
MX2020002150A 2013-08-14 2014-08-07 Terapia de combinación para el tratamiento del cáncer. MX384403B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361865804P 2013-08-14 2013-08-14
US201361894029P 2013-10-22 2013-10-22
PCT/IB2014/063782 WO2015022609A1 (en) 2013-08-14 2014-08-07 Combination therapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2020002150A true MX2020002150A (es) 2021-07-07
MX384403B MX384403B (es) 2025-03-14

Family

ID=51355593

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001793A MX378263B (es) 2013-08-14 2014-08-07 Terapia de combinación para el tratamiento del cáncer.
MX2020002150A MX384403B (es) 2013-08-14 2014-08-07 Terapia de combinación para el tratamiento del cáncer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016001793A MX378263B (es) 2013-08-14 2014-08-07 Terapia de combinación para el tratamiento del cáncer.

Country Status (20)

Country Link
US (9) US20160184311A1 (es)
EP (2) EP4005573A1 (es)
JP (2) JP2016528246A (es)
KR (4) KR102529049B1 (es)
CN (2) CN105828822B (es)
AU (3) AU2014307633A1 (es)
BR (1) BR112016002465B1 (es)
CA (1) CA2918190C (es)
CY (1) CY1124810T1 (es)
DK (1) DK3033086T3 (es)
ES (1) ES2900829T3 (es)
HR (1) HRP20211879T1 (es)
HU (1) HUE057061T2 (es)
LT (1) LT3033086T (es)
MX (2) MX378263B (es)
PL (1) PL3033086T3 (es)
PT (1) PT3033086T (es)
RU (1) RU2680714C2 (es)
SI (1) SI3033086T1 (es)
WO (1) WO2015022609A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20192065T1 (hr) * 2015-06-04 2020-02-21 Pfizer Inc. Čvrsti oblici doziranja palbocikliba
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
WO2017021177A1 (en) * 2015-08-04 2017-02-09 Universitat De Barcelona Pharmaceutical combinations for use in the treatment of cancer
CN107921037A (zh) * 2015-08-28 2018-04-17 诺华股份有限公司 含pi3k抑制剂alpelisib和b‑raf抑制剂达拉菲尼的药物组合；该组合在治疗或预防癌症中的应用
EP3340986A1 (en) * 2015-08-28 2018-07-04 Novartis AG A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
MX2018008321A (es) 2016-01-11 2018-09-21 Syndevrx Inc Tratamiento de tumores ocasionados por disfuncion metabolica.
CN107137409A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
CN107137408A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
SG11201806251WA (en) * 2016-03-15 2018-08-30 Merrimack Pharmaceuticals Inc Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2018001270A1 (en) * 2016-06-30 2018-01-04 Noratech Pharmaceuticals, Inc. Palbociclib prodrugs and composition thereof
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
KR102466192B1 (ko) * 2016-08-23 2022-11-14 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포성 암종의 치료를 위한 조합 요법
CA3056701A1 (en) 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
BR112020001821A2 (pt) * 2017-08-03 2020-07-21 Novartis Ag combinação terapêutica de um inibidor de tirosina quinase de egfr de terceira geração e um inibidor de quinase dependente de ciclina
WO2019097426A1 (en) 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib
US10695333B2 (en) 2017-12-01 2020-06-30 Novartis Ag Pharmaceutical combination comprising LSZ102 and alpelisib
IL281191B (en) 2018-09-07 2022-07-01 Sanofi Sa Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Cdk4/6抑制剂的组合疗法
CN120324434A (zh) * 2020-05-12 2025-07-18 基因泰克公司 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN116940363A (zh) * 2021-03-03 2023-10-24 正大天晴药业集团股份有限公司 Cdk4/6抑制剂的联用药物组合物及其用途
TW202300145A (zh) * 2021-03-24 2023-01-01 大陸商貝達藥業股份有限公司 藥物組合、包含其的試劑盒及其用途
TW202304425A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
TW202304424A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含依維莫司和安森司群的組合
US20240374593A1 (en) * 2021-09-27 2024-11-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition of cdk4/6 inhibitor and aromatase inhibitor
KR102658209B1 (ko) * 2021-10-05 2024-04-18 재단법인 아산사회복지재단 Cdk 억제제 및 id2 활성화제를 포함하는 방광암의 예방 또는 치료용 약학 조성물
CA3238360A1 (en) * 2021-11-18 2023-05-25 Steven M. Fruchtman Methods and compositions for treating cancer
JP2024542633A (ja) * 2021-12-02 2024-11-15 ファイザー・インク がん治療用ｃｄｋ４阻害剤
WO2024107955A1 (en) * 2022-11-17 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
TW202440113A (zh) 2023-03-27 2024-10-16 瑞士商諾華公司 治療早期乳癌之方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
JP2710053B2 (ja) 1988-07-05 1998-02-10 スズキ株式会社 自動車の車体構造
US7196092B2 (en) * 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
BRPI0618042A2 (pt) * 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
BRPI0618473A2 (pt) * 2005-11-11 2011-08-30 Pfizer combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2008009927A1 (en) * 2006-07-18 2008-01-24 Astrazeneca Ab Use of fulvestrant and an aromatase inhibitor for treating breast cancer
KR20130140222A (ko) * 2008-08-22 2013-12-23 노파르티스 아게 Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2010104923A1 (en) * 2009-03-11 2010-09-16 Research Development Foundation Low molecular weight cyclin e (lmw-e) as a biomarker for personalization of cancer therapies
WO2011010349A1 (ja) 2009-07-23 2011-01-27 株式会社アドバンテスト 試験装置
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
JP5918214B2 (ja) * 2010-04-13 2016-05-18 ノバルティス アーゲー がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ
UY34072A (es) * 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
CA2840754A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
WO2019097426A1 (en) * 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib

Also Published As

Publication number Publication date
DK3033086T3 (da) 2022-01-03
US20250170134A1 (en) 2025-05-29
CN110368497B (zh) 2022-05-13
PT3033086T (pt) 2021-12-15
US20250177402A1 (en) 2025-06-05
US20240066034A1 (en) 2024-02-29
HUE057061T2 (hu) 2022-04-28
US20220193079A1 (en) 2022-06-23
JP2019131570A (ja) 2019-08-08
CN105828822A (zh) 2016-08-03
MX2016001793A (es) 2016-05-18
RU2680714C2 (ru) 2019-02-26
CN110368497A (zh) 2019-10-25
AU2019202674A1 (en) 2019-05-16
CA2918190A1 (en) 2015-02-19
MX378263B (es) 2025-03-10
PL3033086T3 (pl) 2022-01-31
US20230398121A1 (en) 2023-12-14
KR102318306B1 (ko) 2021-10-28
KR20230067702A (ko) 2023-05-16
AU2017213541A1 (en) 2017-08-31
EP3033086B1 (en) 2021-09-22
EP3033086A1 (en) 2016-06-22
KR20210132219A (ko) 2021-11-03
BR112016002465A2 (pt) 2017-08-01
US20230405011A1 (en) 2023-12-21
MX384403B (es) 2025-03-14
RU2019104078A (ru) 2019-04-08
AU2014307633A1 (en) 2016-02-11
CA2918190C (en) 2023-01-17
US20240016808A1 (en) 2024-01-18
AU2019202674B2 (en) 2020-07-23
BR112016002465B1 (pt) 2022-09-20
KR20240160682A (ko) 2024-11-11
RU2016108667A3 (es) 2018-07-10
KR20160041920A (ko) 2016-04-18
SI3033086T1 (sl) 2022-01-31
LT3033086T (lt) 2021-12-27
CY1124810T1 (el) 2022-11-25
AU2017213541B2 (en) 2019-01-24
RU2016108667A (ru) 2017-09-14
CN105828822B (zh) 2019-10-18
ES2900829T3 (es) 2022-03-18
KR102736746B1 (ko) 2024-12-03
JP2016528246A (ja) 2016-09-15
HRP20211879T1 (hr) 2022-03-04
US20160184311A1 (en) 2016-06-30
EP4005573A1 (en) 2022-06-01
US20190046533A1 (en) 2019-02-14
KR102529049B1 (ko) 2023-05-08
WO2015022609A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
MX373803B (es) Terapia de combinación que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cáncer.
PH12016502355B1 (en) Pharmaceutical composition
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
WO2014194254A8 (en) Treatment of cancers using pi3 kinase isoform modulators
HK1211475A1 (en) Combination therapy
WO2016133903A3 (en) Combination therapy for cancer treatment
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12016502353A1 (en) Pharmaceutical composition
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12016502352A1 (en) Pharmaceutical composition
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
HK1233917A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy